ROS activated prodrug for ALDH overexpressed cancer stem cells

Miae Won, Ji Hyeon Kim, Myung Sun Ji, Jong Seung Kim

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Aldehyde dehydrogenase (ALDH), a cancer stem cell biomarker, is related to drug resistance. Co-treatment of anti-cancer drug (CPT) and ALDH inhibitor (DEAB) can overcome the drug resistance of cancer stem cells (CSCs) and finally cure cancers without relapse. We herein introduce a prodrug (DE-CPT) - consisting of 1,3-oxathiolane as an ROS responsive scaffold, and an aldehyde protecting group of DEAB - to deliver the CPT and DEAB upon reaction with ROS. From tests of the sphere-forming ability and CSC marker subpopulation, we found that DE-CPT efficiently decreases the CSCs population and kills the cancer cells.

Original languageEnglish
Pages (from-to)72-75
Number of pages4
JournalChemical Communications
Issue number1
Publication statusPublished - 2022 Jan 4

ASJC Scopus subject areas

  • Catalysis
  • Electronic, Optical and Magnetic Materials
  • Ceramics and Composites
  • Chemistry(all)
  • Surfaces, Coatings and Films
  • Metals and Alloys
  • Materials Chemistry


Dive into the research topics of 'ROS activated prodrug for ALDH overexpressed cancer stem cells'. Together they form a unique fingerprint.

Cite this